جست‌وجوی استاد و پژوهشگر

Ali Yetisenمشاهده پروفایل

مدرس ارشد

• Nanotechnology
• Biomedical Engineering
• Medical Biotechnology Diagnostics
• +۳ مورد دیگر

Dr. Ali Yetisen is a Senior Lecturer in the Department of Chemical Engineering at Imperial College London and serves as Director of the Centre for Biochemical Sensors. He specializes in developing biophotonic medical devices, biochemical sensors, and optical materials for applications in medical diagnostics, therapeutics, and imaging. His research focuses on creating wearable and implantable sensors for real-time biomarker monitoring, including projects on contact lens sensors for ocular diagnostics, microneedle patches for glucose monitoring, and holographic bandages for wound assessment. Education : PhD in Chemical Engineering and Biotechnology, University of Cambridge (2011–2014) MEd in Education, Imperial College London (2020–2023) B.S. in Mechanical Engineering, University of Arizona (2010) His research interests span nanotechnology, biomedical engineering, and photonics, with a focus on translating innovations into clinical solutions. Notable work includes engineering living biosensors for dermal tattoos and quantum dot-based lateral flow assays for rapid disease detection. He has held roles such as Tosteson Fellow at Harvard University and currently serves as Warden of Parsons Hall at Imperial College. Research Trends : Recent publications emphasize wearable biosensors, AI-integrated diagnostic systems, and point-of-care technologies. His team’s work bridges engineering and medicine, addressing challenges in diabetes management, glaucoma monitoring, and mental health biomarkers. Advising & Grants : While specific student names or grant details are not listed, his leadership in the Centre for Biochemical Sensors indicates active mentorship of researchers. The Centre collaborates with global academic and industrial partners to advance healthcare technologies. Labs & Teams : The Centre for Biochemical Sensors, housed in Imperial’s Faculty of Engineering, fosters interdisciplinary research with a focus on patient-centric design and open innovation. It includes a Management Board, Researcher Network, and External Advisory Board to drive impactful collaborations.

• Salivary Diagnostics
• Oral Cancer Research
• Genomics
• +۷ مورد دیگر

Dr. David T Wong is a Professor in the Dentistry Department and Head and Neck Surgery at the University of California Los Angeles. With dual appointments across departments, he leads groundbreaking research at the intersection of molecular biology, diagnostics, and oral medicine. His work has established UCLA as a global leader in salivary diagnostics research. Dr. Wong earned his BSc in Biochemistry from Simon Fraser University in 1977, followed by a DMD in Dental Medicine from the University of British Columbia in 1981. He completed advanced training at Harvard with a DMSc in Molecular Biology (1985) and a Certificate in Oral Pathology from Harvard School of Dental Medicine (1985). His research focuses on salivary diagnostics for disease detection, particularly in oral/head and neck cancer. Dr. Wong pioneered the field of "Salivaomics" - the comprehensive study of saliva as a diagnostic fluid containing proteomic, genomic, transcriptomic, metabolomic, and microbiome information. His laboratory spearheads high-throughput technologies to identify genomic and proteomic determinants of oral cancer progression, with emphasis on developing non-invasive diagnostic tools. Key areas include liquid biopsy technologies (particularly saliva-based), extracellular RNA communication, and the development of point-of-care diagnostic devices like the Oral Fluid NanoSensor Test (OFNASET). Analysis of his recent publications reveals a strong trend toward clinical translation of salivary biomarkers, with increasing focus on Sjögren's Syndrome diagnostics, liquid biopsy applications for cancer detection, and the development of novel technologies like EFIRM (Electric Field-Induced Release and Measurement) for ultra-sensitive detection of biomarkers in saliva. His work bridges basic science with clinical applications, particularly in early cancer detection and monitoring. Dr. Wong has received extensive NIH funding as Principal Investigator for numerous projects, including multiple R01, U01, and T32 grants focused on salivary diagnostics, oral cancer biomarkers, and dentist-scientist training programs. His research funding spans over two decades, demonstrating sustained impact and relevance in the field. He leads the Wong Lab, which functions as an interdisciplinary research hub bringing together experts in molecular biology, engineering, dentistry, and oncology. The lab has been instrumental in establishing saliva as a viable biofluid for liquid biopsy applications, particularly for detecting actionable mutations in human cancers. Current research directions include refining EFIRM technology for clinical implementation and expanding the applications of salivary diagnostics to systemic diseases beyond oral conditions.

Shalini Prasadمشاهده پروفایل

استاد

• Bioengineering
• Nanotechnology
• Medical Diagnostics
• +۳ مورد دیگر

Dr. Shalini Prasad is the Cecil H. and Ida Green Professor in Systems Biology Science and Associate Professor of Bioengineering at the University of Texas at Dallas (UT Dallas), affiliated with the Erik Jonsson School of Engineering and Computer Science. She also holds an adjunct professorship in Physics at Portland State University. Her research focuses on developing nanomaterial-based biosensors for medical diagnostics, environmental monitoring, and public health applications. She leads the Biomedical Microdevices and Nanotechnology Lab, which has supported over 50 researchers across graduate and undergraduate levels. Dr. Prasad earned her PhD in Electrical Engineering from the University of California, Riverside (2004) and B.E. in Electronics and Communication Engineering from the University of Madras (2000). Her career includes roles at Portland State University, Arizona State University, and Wichita State University. She has received prestigious awards, including the Bomhoff Distinguished Professorship and the Cecil Green Professorship, and holds over 30 peer-reviewed publications. Her research interests emphasize interdisciplinary approaches to create affordable, portable diagnostic tools for diseases like cancer, neurodegeneration, and cardiovascular disorders, as well as environmental sensors for soil health and water quality. Recent work includes wearable devices for monitoring inflammatory bowel disease and asthma, saliva-based THC detection, and low-cost CO₂/humidity sensors. Awards: Graduate Student Research Award (2004) Bomhoff Distinguished Professor of Bioengineering Cecil H. and Ida Green Professorship Advising & Grants: Dr. Prasad’s lab has secured funding from federal agencies and corporate partners, supporting projects like the SWEAT wearable for chronic inflammation tracking and soil health sensors. Her work bridges engineering, biology, and clinical applications, with a focus on translational technologies. Labs/Teams: Director of the Biomedical Microdevices and Nanotechnology Lab, collaborating on interdisciplinary projects with industry and academic partners.

David R. Raleighمشاهده پروفایل

استادیار

• Neuro-oncology
• Radiation Oncology
• Molecular Mechanisms of Brain Tumors
• +۳ مورد دیگر

David R. Raleigh, MD, PhD, is an Assistant Professor in the Departments of Radiation Oncology and Neurological Surgery at the University of California San Francisco (UCSF). He serves as a Principal Investigator at the Brain Tumor Center and Director of the Preclinical Therapeutics Core. Education: BA in Molecular and Cell Biology and Cognitive Science (UC Berkeley, 2004), MD and PhD in Pathology (University of Chicago, 2012), Residency in Radiation Oncology (UCSF, 2017) His research focuses on the molecular mechanisms of brain tumor growth, particularly meningiomas, integrating developmental biology with oncology to identify novel treatments. Methodologies include biochemistry, mouse genetics, genomics, and pharmacology. Dr. Raleigh's recent publications highlight molecular classification of meningiomas, genomics, and targeted therapies. Awards include Phi Beta Kappa, multiple travel grants, and the Robert and Ruth Halperin Endowed Chair in Meningioma Research.

Rahima Benhabbourمشاهده پروفایل

دانشیار

• Drug Delivery Systems
• Biomedical Engineering
• Polymer Chemistry
• +۷ مورد دیگر

Rahima Benhabbour is an Associate Professor in the Lampe Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill, with an adjunct appointment at the UNC Eshelman School of Pharmacy . Her work bridges polymer chemistry, engineering, and pharmacology to create innovative drug delivery platforms. Ph.D. in Chemistry (McMaster University, 2008) MSc in Medicinal Chemistry (University of Minnesota, 2001) Research focuses on polymer-based biomedical devices for HIV prevention and cancer treatment , emphasizing translational science and 3D-printed intravaginal rings . Articles highlight trends in biomaterials , multipurpose prevention , and nano-delivery systems . KL-2 CTSA Award (2015-2018) for HIV prophylaxis research Teaches BMME 890 - Special Topics and BMME 900 - Research in Biomedical Engineering . Lab is affiliated with the Center in Nanotechnology and Drug Delivery and collaborates with clinical experts in HIV/oncology.

Andrew Godwinمشاهده پروفایل

استاد

• Molecular Oncology
• Precision Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

David Gillattمشاهده پروفایل

استاد

• Urological Oncology
• Robotic Surgery
• Prostate Cancer Diagnosis
• +۵ مورد دیگر

Professor David Gillatt is a leading urological oncologist and robotic surgeon at Macquarie University, specializing in prostate and bladder cancer treatments. He holds roles as Director of Medical and Surgical Services at MQ Health, Head of Urology Clinical Discipline, and Professor of Urological Oncology and Robotics. With over 25 years of experience, he has performed over 2,000 major resections and pioneered the Enhance Recovery program for cystectomy, a globally recognized innovation. His clinical expertise includes robotic surgery training programs and advanced pelvic cancer surgery. Education and Qualifications: Gillatt holds a Bachelor of Surgery and Medicine from the University of Manchester (1980), Fellowships from the Royal College of Surgeons of England (1993), Edinburgh (1984), and the Royal Australasian College of Surgeons (2015). Research Focus: His work spans clinical trials and basic science, including biomarker discovery for prostate cancer (e.g., IGFs and volatile diagnostics) and the impact of ketamine abuse on bladder function. He led the Bristol Chief Investigator role for the national PROTECT study and established the Prostate Cancer Care and Research Centre in the UK. Projects and Collaborations: Key projects include robotic surgery training methodologies, high-dose vitamin D trials for prostate cancer (Pros-D), and molecular imaging advancements for bladder cancer using upconversion nanoparticles. Awards and Recognition: His fellowships (FRCS, FRACS) and contributions to global urological advancements highlight his expertise. He is recognized for strengthening Macquarie’s multidisciplinary prostate cancer care model. Labs and Teams: He leads surgical and research teams at Macquarie University Hospital, collaborating on bioreactor technologies and cancer radioimmunotherapy initiatives.

• Tumor Microenvironment
• Magnetic Resonance Imaging (MRI)
• Quantitative Imaging Biomarkers
• +۵ مورد دیگر

Professor Sungheon Gene Kim holds a faculty position at the Weill Cornell Medicine Graduate School of Medical Sciences within the Department of Radiology . His research focuses on quantitative MRI methodology for oncological applications , particularly in breast cancer and head and neck cancer . Kim's lab develops advanced dynamic contrast-enhanced MRI (DCE-MRI) and diffusion MRI (dMRI) techniques to assess tumor microenvironment and treatment response . Key research areas include: Tumor vascular properties via 3D UTE-GRASP MRI Cellular microstructural analysis through POMACE framework Adipose-tissue cancer interaction via MR spectroscopic imaging His lab has received continuous funding from the National Cancer Institute (R01CA219964, UG3/UH3CA228699, R01CA160620). Recent publications demonstrate technical advancements in ultrafast MRI reconstruction , deep learning-enhanced perfusion analysis , and multi-parametric tumor characterization . Collaborations with the National Institutes of Health Quantitative Imaging Network have produced novel cellular water exchange rate measurements that correlate with patient survival outcomes .

Yong Zengمشاهده پروفایل

دانشیار

• Precision Medicine
• Nanotechnology
• Biomarker Development
• +۶ مورد دیگر

Yong Zeng is an Associate Professor in the Department of Chemistry at the University of Florida. He leads the Zeng Group, focusing on precision medicine through innovative micro/nanoscale technologies. His research bridges chemistry, materials science, bioengineering, and medicine to develop tools for non-invasive cancer and Alzheimer’s disease diagnosis. Key projects include lab-on-a-chip systems, exosome-based liquid biopsy platforms, and CRISPR-driven diagnostic assays. Education: Ph.D., Chemistry, University of Alberta (2007) Postdoctoral Research, University of California, Berkeley (2008-2012) Research Interests: Dr. Zeng’s work centers on creating transformative technologies for precision diagnostics, including nano-engineered microfluidic devices, smart bioanalyzers with AI integration, and exosome-based biomarker analysis. His group has pioneered methods for detecting extracellular vesicles, proteins, nucleic acids, and glycans in blood samples. Awards: 2013 Bioanalysis Young Investigator Award Grants & Collaborations: Supported by NIH grants, his lab collaborates with clinicians and biologists to translate technologies into clinical tools. Notable collaborations include exosome research for precision immunotherapy and liquid biopsy-based cancer diagnosis. Labs/Teams: The Zeng Group operates at the interface of engineering and medicine, emphasizing translational research to bridge laboratory innovations with clinical applications.

Can Dincerمشاهده پروفایل

استاد

• Bioanalytical Materials
• Sensors and Microsystems
• Data Science
• +۴ مورد دیگر

Prof. Can Dincer is a Professor of Sensors and Wearables for Healthcare at the TUM School of Computation, Information and Technology, Technische Universität München (TUM). His research focuses on bioanalytical materials, wearable sensors, and AI-driven diagnostics for One-Health applications, integrating disposable sensor technology with data science. He holds a doctorate from the University of Freiburg (summa cum laude, 2016) and worked as a visiting scientist at Imperial College London before joining TUM in 2024. He is a member of the Munich Institute of Biomedical Engineering (MIBE). Key research interests include: Development of wearable biosensors for real-time health monitoring CRISPR-based diagnostics for nucleic acids and proteins AI integration for therapeutic drug monitoring in sepsis and other critical conditions Environmental health connections via point-of-need diagnostics Notable achievements include the 2021 Biosensors & Bioelectronics Best Paper Award and inclusion in Stanford's World's Top 2% Scientists since 2022. His work spans clinical applications, microfluidic platforms, and nanotechnology-based solutions for healthcare challenges. Publications highlight innovations like optogenetic bioassays (Science Advances, 2024), CRISPR-powered multiplexed biosensors, and wearable systems for continuous biomarker monitoring. His research bridges material science, electrical engineering, and biomedicine to create practical diagnostic tools. Prof. Dincer collaborates across disciplines, focusing on translating lab innovations into clinical and commercial applications through advanced sensor technologies.

Cristian Tomasettiمشاهده پروفایل

استاد

• Cancer Etiology
• Mathematical Oncology
• Cancer Evolution
• +۵ مورد دیگر

Cristian Tomasetti serves as Professor and Director of the Early Detection and Prevention Division at City of Hope's Beckman Research Institute, where he leads the Division of Mathematics for Cancer Evolution and Early Detection within the Department of Computational and Quantitative Medicine. His work bridges mathematical modeling with cancer biology to develop novel approaches for cancer detection and prevention. Dr. Tomasetti's research focuses on the mathematical foundations of cancer etiology, evolution, and early detection. His laboratory has pioneered algorithms for early cancer detection using cell-free DNA sequencing and protein data, developing some of the first multi-analyte blood tests capable of identifying cancer at its earliest stages. His work on cancer evolution has produced the most comprehensive mathematical models of tumorigenesis currently available, providing critical insights into mutation rates, driver gene requirements, and fitness advantages in cancer development. His influential research on the relationship between stem cell divisions and cancer risk has reshaped understanding of cancer etiology. The analysis of Dr. Tomasetti's recent publications reveals a consistent focus on liquid biopsy technologies, particularly circulating tumor DNA analysis for early cancer detection and monitoring. His work spans multiple cancer types including colorectal, pancreatic, ovarian, and bladder cancers, with a strong emphasis on translating mathematical models into clinically applicable diagnostic tools. The research demonstrates an evolution from theoretical models of cancer development to practical applications in cancer screening, risk assessment, and treatment monitoring. Dr. Tomasetti has established himself as a leader in the field of mathematical oncology, with his laboratory at the forefront of developing computational approaches to cancer prevention and early detection. His work on cell-free DNA testing has significant potential to transform cancer screening paradigms, moving toward less invasive and more effective methods for detecting cancer before symptoms appear.

Stuart Robertsمشاهده پروفایل

عضو هیئت علمی

• Hepatology
• Chronic Viral Hepatitis
• Primary Liver Cancer
• +۹ مورد دیگر

Stuart Roberts is an Adjunct Clinical Professor in the Department of Gastroenterology at Monash University, Faculty of Medicine, Nursing and Health Sciences. He is actively engaged in clinical research focusing on liver diseases, with a strong emphasis on chronic viral hepatitis, primary liver cancer, non-alcoholic fatty liver disease (NAFLD/MASLD), and non-invasive liver diagnostics such as Fibroscan. University: Monash University School: Faculty of Medicine, Nursing and Health Sciences Department: Department of Gastroenterology Academic Rank: Adjunct Clinical Professor His research interests center on advancing therapeutic strategies for chronic liver diseases through clinical trials and translational studies. Key areas include evaluating novel antiviral and immunomodulatory agents for hepatitis B and C, assessing new treatments for hepatocellular carcinoma, and investigating metabolic and dietary influences on liver health in aging populations. He also studies the role of liver stiffness measurement in disease screening and prognosis. The recent publications and active research projects (2024–2025) reflect a strong trend toward understanding the intersection of liver disease with aging, cardiovascular health, and neurocognitive outcomes. His work increasingly focuses on metabolic dysfunction-associated steatotic liver disease (MASLD), its systemic complications, and lifestyle or pharmacological interventions. Multiple phase 1 to phase 3 clinical trials are underway, particularly in NASH/MASH, hepatitis B immunotherapy, and cholangiocarcinoma. Scientific Awards: No awards mentioned in the provided text. Advising and Grants: Dr. Roberts serves as Primary Chief Investigator on 42 research projects, including major industry-sponsored clinical trials in hepatology. His leadership in multicenter studies highlights his role in shaping evidence-based liver disease management. While no formal student advising is mentioned, his collaborations involve trainees and junior researchers. Funding appears to come from pharmaceutical sponsors and institutional sources, supporting trials in antiviral, metabolic, and oncologic liver therapies. Labs and Research Teams: Dr. Roberts leads a clinical research team focused on hepatology within Monash Health. His work is highly collaborative, involving dietitians, oncologists, geriatricians, and neurologists. The research network includes national and international partners, with a strong presence in Australian multicenter liver disease studies.

Karl Bertlingمشاهده پروفایل

مدرس ارشد

• Laser Feedback Interferometry
• Terahertz Imaging
• Biomedical Engineering
• +۳ مورد دیگر

Dr. Karl Bertling is a Senior Lecturer in the School of Electrical Engineering and Computer Science at The University of Queensland (UQ). His research focuses on pioneering imaging and sensing techniques using laser feedback interferometry (LFI), particularly with terahertz quantum cascade lasers (QCLs). Key areas include early melanoma detection, agricultural photonics, and near-field terahertz imaging of nanomaterials. He holds a PhD in Engineering from UQ (2012) and has authored over 140 publications in journals like Optics Express and IEEE Transactions . His work spans diverse applications: from biomedical imaging to cultural heritage preservation, leveraging LFI for non-destructive analysis. Collaborations include projects with institutions like the Queensland Brain Institute and industry partners. Bertling’s expertise bridges materials science, photonics, and quantum technologies, with contributions to THz nanoscopy and quantum device characterization. Research interests include: Terahertz QCL-based imaging and sensing Biomedical applications: skin pathologies and cancer detection Agricultural monitoring via terahertz hydration sensing Nanostructure analysis using THz nanoscopy Grants and funding: Multiple Australian Research Council (ARC) grants and industry partnerships support his work. Ongoing projects explore THz photonics for precision agriculture and quantum material characterization.

• Infectious Diseases
• Transplant Medicine
• Invasive Fungal Infections
• +۳ مورد دیگر

Dr. Daniel Friedman is an Assistant Professor in the Department of Medicine-Infectious Diseases at the University of Chicago. His clinical and research focus centers on managing infectious diseases in immunocompromised patients, particularly those undergoing solid organ or stem cell transplants, cancer treatments, or other high-risk conditions. He specializes in pre-transplant infection risk assessment, personalized preventive strategies, and invasive fungal infections in transplant recipients. His research also explores novel antifungal therapies and the epidemiology of infections in immunosuppressed populations. Dr. Friedman has been actively involved in clinical trials for emerging antifungal treatments and diagnostic methods. His work bridges translational research and clinical care, with a strong emphasis on improving outcomes for high-risk patients. Notable collaborations include studies on risk factors for invasive aspergillosis in kidney transplant recipients and the impact of non-tuberculous mycobacteria on lung transplant outcomes. His publications span topics such as fungal diagnostics, antifungal drug efficacy, and infection management in transplant recipients. He has co-authored studies on Pneumocystis jirovecii pneumonia in renal transplant patients and SARS-CoV-2 considerations in liver transplantation. His research networks include collaborations with institutions like the Mayo Clinic and the University of Alberta, focusing on infectious disease epidemiology and clinical trials.

• Medical Biotechnology
• Genetic Engineering
• Antibody Engineering
• +۴ مورد دیگر

Gordana Wozniak-Knopp is a researcher at the University of Natural Resources and Life Sciences, Vienna (BOKU), affiliated with the Institute of Molecular Biotechnology under the Department of Biotechnology and Food Science. Her work focuses on antibody engineering, molecular biotechnology, and protein stability optimization. Key research areas include Development of multispecific antibodies using controlled Fab-arm exchange and SEED technology Engineering antigen-binding sites in Fc regions Stabilization of antibody fragments via disulfide bonds and domain exchange Extracellular vesicle functionalization for targeted drug delivery Design of diagnostic antibody microarrays and SARS-CoV-2 antigen platforms Between 2020–2024, she led an FWF-funded project on therapeutic antibodies for birch pollinosis and a 2016–2023 CD Laboratory for Innovative Immunotherapeutics. Her recent publications (2022–2023) emphasize trispecific antibody design, SARS-CoV-2 diagnostics, and CD81-based delivery systems. Scientific contributions include peer-review activities for journals like Protein Science , Nature Communications , and Scientific Reports , along with organizing events such as the Lange Nacht Der Forschung 2024 . She actively participates in international conferences and project evaluations for organizations like Poland’s National Science Centre.